omeprazole has been researched along with Exocrine Pancreatic Insufficiency in 8 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Exocrine Pancreatic Insufficiency: A malabsorption condition resulting from greater than 10% reduction in the secretion of pancreatic digestive enzymes (LIPASE; PROTEASES; and AMYLASE) by the EXOCRINE PANCREAS into the DUODENUM. This condition is often associated with CYSTIC FIBROSIS and with chronic PANCREATITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution." | 9.10 | Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. ( De Boeck, K; Proesmans, M, 2003) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 9.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "To compare, during strong acid inhibition with omeprazole, the effect of 2 different doses of an enteric-coated pancreatic enzyme preparation on fecal fat excretion and abdominal symptoms in patients with exocrine insufficiency due to chronic pancreatitis (CP)." | 5.12 | Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. ( Lamers, CB; Masclee, AA; Symersky, T; Vecht, J, 2006) |
| "Omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution." | 5.10 | Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. ( De Boeck, K; Proesmans, M, 2003) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 5.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "Chronic pancreatitis was alcohol-related in 23 patients, previous surgery was performed in 9, 16 had diabetes and all had steatorrhoea (fat balance > 10g/24h)." | 2.68 | Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis. ( Buedts, K; Cremer, M; Delhaye, M; Gohimont, AC; Meuris, S, 1996) |
| "Pancreatic insufficiency is the second most important pathophysiological expression of cystic fibrosis (CF) and occurs in the majority of patients." | 2.38 | New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis. ( Heijerman, HG, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Proesmans, M | 1 |
| De Boeck, K | 1 |
| Domínguez-Muñoz, JE | 1 |
| Iglesias-García, J | 1 |
| Iglesias-Rey, M | 1 |
| Vilariño-Insua, M | 1 |
| Vecht, J | 1 |
| Symersky, T | 1 |
| Lamers, CB | 2 |
| Masclee, AA | 1 |
| Bruno, MJ | 1 |
| Rauws, EA | 1 |
| Hoek, FJ | 1 |
| Tytgat, GN | 1 |
| Delhaye, M | 1 |
| Meuris, S | 1 |
| Gohimont, AC | 1 |
| Buedts, K | 1 |
| Cremer, M | 1 |
| Hendriks, JJ | 1 |
| Kester, AD | 1 |
| Donckerwolcke, R | 1 |
| Forget, PP | 1 |
| Wouters, EF | 1 |
| Heijerman, HG | 1 |
| Jansen, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen[NCT01430234] | Phase 4 | 10 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Exocrine Pancreatic Insufficiency
| Article | Year |
|---|---|
New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis.
Topics: Cystic Fibrosis; Drug Therapy, Combination; Exocrine Pancreatic Insufficiency; Humans; Omeprazole; P | 1992 |
5 trials available for omeprazole and Exocrine Pancreatic Insufficiency
| Article | Year |
|---|---|
Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.
Topics: Adolescent; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship | 2003 |
Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency.
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Exocrine Panc | 2006 |
Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy.
Topics: Adult; Aged; Celiac Disease; Cimetidine; Double-Blind Method; Exocrine Pancreatic Insufficiency; Fem | 1994 |
Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
Topics: Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Exocrine Pancreatic Ins | 1996 |
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height; | 2001 |
2 other studies available for omeprazole and Exocrine Pancreatic Insufficiency
| Article | Year |
|---|---|
Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts.
Topics: Adult; Aged; Exocrine Pancreatic Insufficiency; Female; Humans; Male; Middle Aged; Omeprazole; Pancr | 2006 |
Omeprazole as adjunct to enzyme replacement in severe pancreatic insufficiency.
Topics: Exocrine Pancreatic Insufficiency; Female; Humans; Male; Middle Aged; Omeprazole; Pancreas | 1986 |